British Health Secretary Matt Hancock has said he cannot give any assurances that the current vaccines the UK has against Covid-19 will be as effective against the new variant of the virus that originated in India.
Replying to a question asked by India-origin Labour MP Tanmanjeet Singh Dhesi in Parliament to the Secretary of State for Health and Social Care on Monday, the UK government confirmed they do not know whether the UK's vaccination programme will be effective against the Indian Covid-19 variant.
"We are acting on a precautionary basis because I can't give him that assurance. And, of course, we are looking into that question as fast as possible. But that is the core of my concern about the variant first found in India. Is that the vaccines may be less effective, in terms of transmission and/or in terms of reducing hospitalisation and death.
"It is the same concern that we have with the variant found in South Africa and is the core reason why we took this decision today, said Hancock.
This follows India being placed on the 'red list' for travel and Prime Minister Boris Johnson cancelling his trip to the country.
Dhesi asked: "The Prime Minister cancelled his India trip and the government just announced that India has been placed on its travel 'red list', amid devastating surge in Covid cases there. But Health Secretary is still unsure if our vaccines are effective against the new double mutation variant detected there."
The National Centre for Disease Control (NCDC) has reported that a "new double mutant variant" of the coronavirus has been found in India.
It has been named a 'Desi' (Indian) variant.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)